You are here

Clinical Trials

Developers to file NDA in second half of 2017
CTSA program paves way for nationwide single IRB model
FDA approval decision expected in April
NKTR-181 doesn’t cause the euphoria that can lead to abuse and addiction
Twice-a-year inclisiran scores in mid-stage trial
Drug inhibits proprotein convertase subtilisin/kexin type 9
Researchers debunk venoplasty procedure
Ublituximab/ibrutinib combo improves response rate versus ibrutinib alone
Company foresees big savings for Medicare and private insurance firms
Company walks away from protein-restoration therapy
Roche protects aging oncology franchise